Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) EPS (Weighted Average and Diluted) (2021 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$0.31 as the latest value for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) changed N/A year-over-year to -$0.31; the TTM value through Sep 2025 reached -$0.31, changed N/A, while the annual FY2023 figure was $3.14, 410.41% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$0.31 in Q3 2025 for Cyclerion Therapeutics, up from -$0.54 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $5.86 in Q3 2023 and bottomed at -$6.16 in Q2 2022.
  • Average EPS (Weighted Average and Diluted) over 4 years is -$0.41, with a median of -$0.3 recorded in 2022.
  • Year-over-year, EPS (Weighted Average and Diluted) crashed 1268.89% in 2022 and then soared 2542.0% in 2023.
  • Cyclerion Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.24 in 2021, then surged by 33.33% to -$0.16 in 2022, then skyrocketed by 3763.01% to $5.86 in 2023, then plummeted by 105.32% to -$0.31 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.31, -$0.54, and -$0.57 for Q3 2025, Q2 2025, and Q1 2025 respectively.